Sponsors (9)
The bill aims to lower drug prices and curb PBM/insurer vertical integration by forcing divestitures and strengthening enforcement and private lawsuits, but it risks short‑term disruptions to pharmacy services, higher litigation and compliance costs, and potential economic burdens that could be passed to consumers, businesses, or taxpayers.
Patients (including Medicare and Medicaid enrollees and people with chronic conditions) could pay lower drug prices because the bill forces divestiture of vertically integrated PBMs/insurers from pharmacies and reduces PBM self‑preferencing and anti‑competitive price‑setting.
Federal and state enforcers would have clearer authority to block or unwind anti‑competitive vertical integrations, improving accountability and preventing future consolidation that can raise prices or reduce consumer choice.
Individuals harmed by anti‑competitive vertical integration (patients and consumer groups) can sue with a private right of action and seek treble damages and attorney’s fees, increasing deterrence and the chance of compensation for overcharges.
Patients (including Medicare beneficiaries and those with chronic conditions) and some pharmacies could experience disrupted access to services (retail, mail order, specialty) during forced divestitures or rapid restructurings, risking interruptions in medication supply or care.
Businesses (PBMs, insurers, pharmacies) and governmental bodies may face higher litigation and regulatory compliance costs—including more private lawsuits and treble‑damages claims—which can increase legal uncertainty and potentially raise consumer prices if costs are passed on.
Divestiture and restructuring costs for affected companies could be substantial and may be passed through to consumers, employers, or taxpayers as higher prices or reduced services.
Based on analysis of 3 sections of legislative text.
Prohibits ownership of both pharmacies and PBMs/insurers, requires divestiture within one year, and creates public and private enforcement with injunctive and monetary remedies.
Official title: To prohibit pharmacy benefit managers and pharmacies from being under common ownership, and for other purposes.
Introduced May 13, 2026 by Diana Harshbarger · Last progress May 13, 2026
Prohibits any person or company from owning or controlling both a pharmacy (retail or otherwise) and a pharmacy benefit manager (PBM) or an insurance company, and requires divestiture of pharmacies owned by entities that also own PBMs or insurers within one year of enactment. It creates enforcement authorities for the Federal Trade Commission (FTC), the Department of Justice (Antitrust Division), state attorneys general, and private plaintiffs, and establishes remedies including mandatory divestiture, disgorgement, treble damages for private plaintiffs, escrowed profit penalties for missed milestones, and appointment of divestiture trustees where needed. Also sets out congressional findings about PBM market concentration and vertical integration and directs the FTC and DOJ to issue guidance and use expanded review and enforcement powers to block or unwind transactions that recreate vertical conflicts. Funds from disgorgement or escrow that are not returned are directed into an FTC-created fund to benefit harmed communities.